252 related articles for article (PubMed ID: 34520029)
1. Patient satisfaction with clinic-based medication pick up: Addressing pharmacy-level challenges to buprenorphine access.
Kolb E; Rueth M
J Opioid Manag; 2021; 17(7):77-86. PubMed ID: 34520029
[TBL] [Abstract][Full Text] [Related]
2. Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
Khan A; Khan Q; Kolb E
J Subst Abuse Treat; 2021 Apr; 123():108256. PubMed ID: 33612191
[TBL] [Abstract][Full Text] [Related]
3. Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies.
Freeman PR; Hammerslag LR; Ahrens KA; Sharbaugh M; Gordon AJ; Austin AE; Donohue JM; Allen LD; Barnes AJ; Talbert JC
JAMA Health Forum; 2024 May; 5(5):e241077. PubMed ID: 38758569
[TBL] [Abstract][Full Text] [Related]
4. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
Textor L; Ventricelli D; Aronowitz SV
Int J Drug Policy; 2022 Jul; 105():103703. PubMed ID: 35561484
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of unclaimed prescriptions at military pharmacies.
Esposito D; Schone E; Williams T; Liu S; CyBulski K; Stapulonis R; Clusen N
J Manag Care Pharm; 2008; 14(6):541-52. PubMed ID: 18693778
[TBL] [Abstract][Full Text] [Related]
6. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
[TBL] [Abstract][Full Text] [Related]
7. Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility.
Ostrach B; Hill L; Carpenter D; Pollini R
J Am Pharm Assoc (2003); 2023; 63(4):1044-1048. PubMed ID: 37149144
[TBL] [Abstract][Full Text] [Related]
8. Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.
Kazerouni NJ; Irwin AN; Levander XA; Geddes J; Johnston K; Gostanian CJ; Mayfield BS; Montgomery BT; Graalum DC; Hartung DM
Drug Alcohol Depend; 2021 Jul; 224():108729. PubMed ID: 33932744
[TBL] [Abstract][Full Text] [Related]
9. Ensuring buprenorphine access in rural community pharmacies to prevent overdoses.
Ostrach B; Potter R; Wilson CG; Carpenter D
J Am Pharm Assoc (2003); 2022; 62(2):588-597.e2. PubMed ID: 34674965
[TBL] [Abstract][Full Text] [Related]
10. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
[TBL] [Abstract][Full Text] [Related]
11. Switching pharmacies leads to gaps in medication possession in individuals treated with buprenorphine.
Varisco TJ; Abughosh S; Chen H; Cho SK; Fleming ML; Ziedonis D; Thornton D
J Am Pharm Assoc (2003); 2021; 61(5):589-595. PubMed ID: 34016547
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study.
Suzuki J; Zinser J; Klaiber B; Hannon M; Grassi H; Spinosa M; Ramirez A; Issa M; Chin Feman SP
Subst Abus; 2015; 36(2):166-9. PubMed ID: 25738320
[TBL] [Abstract][Full Text] [Related]
13. A retrospective cohort study of medication dispensing at pharmacies: Administration matters!
Hesse M; Thylstrup B; Seid AK; Tjagvad C; Clausen T
Drug Alcohol Depend; 2021 Aug; 225():108792. PubMed ID: 34118551
[TBL] [Abstract][Full Text] [Related]
14. Readiness of community pharmacies to implement an opioid safety intervention.
Floyd AS; Silcox J; Cousin E; Irwin AN; Gray M; Bolivar D; Bratberg J; Arnold J; Al-Jammali Z; Hansen RN; Hartung DM; Green TC
J Am Pharm Assoc (2003); 2023; 63(1):275-283.e1. PubMed ID: 36496310
[TBL] [Abstract][Full Text] [Related]
15. Allowing central fill pharmacies and retail pharmacies to fill prescriptions for controlled substances on behalf of retail pharmacies. Final rule.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 2003 Jun; 68(121):37405-11. PubMed ID: 12836645
[TBL] [Abstract][Full Text] [Related]
16. Users of retail medications for opioid use disorders faced high out-of-pocket prescription spending in 2011-2017.
McClellan C; Moriya A; Simon K
J Subst Abuse Treat; 2022 Jan; 132():108645. PubMed ID: 34728135
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.
Wu LT; John WS; Ghitza UE; Wahle A; Matthews AG; Lewis M; Hart B; Hubbard Z; Bowlby LA; Greenblatt LH; Mannelli P;
Addiction; 2021 Jul; 116(7):1805-1816. PubMed ID: 33428284
[TBL] [Abstract][Full Text] [Related]
18. Eligible Prescriber Experiences with Substance Use Disorder Treatment and Perceptions of Pharmacy Barriers to Buprenorphine.
Harless JC; Hughes PM; Wilson C; Carpenter D; Ostrach B
South Med J; 2022 Aug; 115(8):584-592. PubMed ID: 35922043
[TBL] [Abstract][Full Text] [Related]
19. Community Pharmacists' Knowledge and Perceptions of Buprenorphine for Patients with Opioid Use Disorder.
Tutag Lehr V; Nolan C
J Addict Med; 2023 Jul-Aug 01; 17(4):e224-e231. PubMed ID: 37579094
[TBL] [Abstract][Full Text] [Related]
20. Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists.
Hill LG; Light AE; Green TC; Burns AL; Sanaty Zadeh P; Freeman PR
J Am Pharm Assoc (2003); 2023; 63(1):252-260.e6. PubMed ID: 36202711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
